Lanean...
Progress and challenges for treating Type 1 diabetes
It has been more than 30 years since the initial trials of Cyclosporin A to treat patients with new onset Type 1 diabetes (T1D). Since that time, there have been insights into genetic predisposition to the disease, the failures of immune tolerance, and mechanisms that cause the immune mediated β cel...
Gorde:
| Argitaratua izan da: | J Autoimmun |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4903889/ https://ncbi.nlm.nih.gov/pubmed/27210268 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jaut.2016.04.004 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|